... out of more than 90 vaccines entering HVTN Phase I testing chosen to progress to Phase II clinical trials. Both HIV/AIDS vaccine and treatment markets are huge and GOVX has the potential to be a key player in the two markets. Management will ...
http://www.dailypolitical.com/finance/stock-market/geovax-labs-rating-reiterated-by-zacks-govx.htm
http://www.dailypolitical.com/finance/stock-market/geovax-labs-rating-reiterated-by-zacks-govx.htm
No comments:
Post a Comment